RYTM - Rhythm Pharma reports positive setmelanotide data in MC4R pathway deficiency-related obesities

Rhythm Pharmaceuticals (RYTM) announces positive data from multiple cohorts in its Phase 2 Basket Study evaluating setmelanotide for the treatment of severe obesity due to genetic variants in the melanocortin-4 receptor (MC4R) pathway.Clinical data from five cohorts totaling 65 patients demonstrated proof-of-concept in HET POMC, PCSK1 or LEPR deficiencies, SRC1 and SH2B1 deficiency obesities. The primary endpoint is the percent of patients showing at least a 5% loss of body weight over three months.New data show that setmelanotide led to meaningful weight loss in ~30% to greater than 50% of treated patients with genetic variants in the MC4R pathway across multiple genes. Consistent with prior clinical experience, setmelanotide was generally well tolerated in each of these rare genetic diseases of obesity. There were no serious adverse events. The Company is in discussions with the FDA to define a potential path for setmelanotide towards registration for these indications.Pending outcome, Rhythm plans

For further details see:

Rhythm Pharma reports positive setmelanotide data in MC4R pathway deficiency-related obesities